Anna Mae Diehl, MD
Dr. Diehl is a leading researcher in the field of nonalcoholic fatty liver disease (NAFLD) with a long standing interest in liver injury and repair. She is currently the Director of the Duke Liver Center and the Florence McAlister Professor of Medicine at the Duke University School of Medicine.
Dr. Diehl has conducted seminal research in many areas, including liver regeneration, the role of cytokines in liver disease, and hepatocellular cancer. In addition, she has conducted the definitive work in understanding the important role of Hedgehog signaling proteins in liver pathobiology, from liver regeneration, to hepatic fibrosis, to activation of stellate cells, growth of progenitor cells, and development of cirrhosis. Dr. Diehl was also one of the first researchers to demonstrate that fatty liver is not a reversible innocuous condition, but a frequent cause of severe liver damage, evolving into non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.
Dr. Diehl has been an active participant in the NIDDK-funded Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), a national consortium comprised of 8 university medical centers selected to generate a national registry for patients with NAFLD and to conduct multicenter treatment trials for this disorder. Diehl has received extensive grant funding from the National Institutes of Health and has authored more than 250 peer-reviewed articles. She is a recipient of numerous awards, including the Leon Schiff Award, the Hans Popper Award, the Sheila Sherlock Award from the British Society of Gastroenterology, and the American Association for the Study of Liver Diseases Distinguished Achievement Award.
She received her M.D. from Georgetown University, followed by residency and a fellowship in gastroenterology at Johns Hopkins University.